Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Asimov and RevOpsis Therapeutics
    20 November 2024

    Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

    Strategic agreement will accelerate the manufacturing of fully human multispecific therapies for chronic retinal diseases with high unmet need using Asimov’s CHO Edge System ...

    Steritas LLC
    20 November 2024

    Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics

    First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, announces a ...

    Enterprise Therapeutics
    19 November 2024

    Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

    Paper in the European Journal of Medicinal Chemistry discloses the optimisation process leading to the selection for development of ETD001, an inhaled ENaC blocker with a best-in-class profile ETD001 commenced Phase 2 clinical study in people with cystic fibrosis in July 2024 Brig...

    Turing Locke Courtyard
    19 November 2024

    The importance of choosing sustainable accommodation for winter travel

    Winter is a time for cosy getaways, snowy adventures, and festive experiences, but it’s also a season that puts added pressure on the environment. Increased energy use for heating, high water demand, and waste generation can make winter travel a challenging time to be eco-friendly. One ...

    www.sapiosciences.com
    19 November 2024

    Sapio Sciences collaborates with Waters Corporation to improve efficiency of laboratory operations

    The advanced connectivity of Sapio LIMS with waters_connect for Quantitation liquid chromatography mass spectrometry (LC-MS) software Baltimore, MD, 18 November 2024 – Sapio Sciences, the science-aware™ lab informatics platform, announces it has entered a co-marketing agreement with Wa...

    Pierre Arsène, Founder and CEO, Mursla Bio
    18 November 2024

    Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

    EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection Data pr...

    Tom's Trust
    18 November 2024

    First ever UK-wide project launched to explore the inequality in access to psychological care within childhood brain tumour services

    A pilot year-long project studying the inequality in access to psychological care within childhood brain tumour services, and the implications on access to clinical trials, has been launched by a team at the Great North Children’s Hospital in Newcastle. The project has been funded by ch...

    move
    15 November 2024

    Cleancube Multi: Guardtech Group’s shipping container facilities helping NHS Aseptic Pharmacies MOVE forward

    Suffolk contamination control experts’ award-winning Cleancube Mobile Cleanrooms proving to be perfect solution for Trusts that require facility upgrades ...

    Men's Day Speakers Deliver Their Talks to 100 Attendees
    13 November 2024

    100 guests including local sixth form students attend International Men's Day talks and wellbeing workshop at SBC

    We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst. As part of our series of diversity and inclusion events this year, which have included International Women’s Day and PRIDE, we hosted talks, a Q&A and a wellbeing workshop to pr...

    CN Bio’s PhysioMimix Bioavailability assay kit: Human 18
    14 November 2024

    CN Bio launches PhysioMimix Bioavailability assay kit: Human 18

    Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to accelerate and de-risk clinical progression of drug candidates Supports up to 18 data repl...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 109
    • Page 110
    • Current page 111
    • Page 112
    • Page 113
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS